LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced that Garo Armen, PhD, Chief Executive Officer, and Robert Stein, MD, PhD, Chief Scientific Officer, will conduct a series of one-on-one meetings with investors at the FBR Inaugural Healthcare Conference on Wednesday, September 3 in Boston.
Agenus management will also present a Company overview at the Rodman & Renshaw 16th Annual Healthcare Conference in New York City on Tuesday, September 9 at 9:10 a.m. EDT.
The live and archived webcast of the presentation will be accessible from the Company’s website atwww.agenusbio.com/webcast. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Agenus website for one month following the conference.
Agenus is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40, LAG-3, TIM-3, CTLA-4 and PD-1, critical targets in co-stimulatory and inhibitory pathways regulating self-tolerance and immune responses to tumor antigens. Checkpoint modulators represent an important new class of cancer immunotherapeutics. The Company’s proprietary discovery engine, Retrocyte Display,® is used to generate fully human and humanized therapeutic antibody drug candidates. The Retrocyte Display platform uses IgG format human antibody libraries expressed in mammalian B-lineage cells, to generate antibodies with high potency and specificity, and with no re-engineering requirement. Agenus’ Prophage heat shock protein vaccines recently generated positive data in phase 2 studies in newly diagnosed gliobastoma (the most common and most aggressive malignant primary brain cancer) and in genital herpes (an incurable infectious disease afflicting over 40 million adults in the United States). The Company’s QS-21 Stimulon® adjuvant is a key component in the development of several investigational vaccines across a wide variety of infectious diseases, and therapeutic vaccines intended to treat cancer and degenerative disorders. The QS-21 platform is extensively partnered with GlaxoSmithKline and Janssen and includes two candidates in phase 3 trials for melanoma and shingles. A regulatory application was filed recently by GlaxoSmithKline with the EMA, and has been accepted for review, following positive results in a phase 3 trial in malaria. For more information, please visit www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+. For more information, please visit www.agenusbio.com.
This press release contains forward-looking statements, including statements regarding the Company’s upcoming corporate presentation. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the period ended June 30, 2014. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Agenus undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Agenus’ business is subject to substantial risks and uncertainties, including those identified above. When evaluating Agenus’ business and securities, investors should give careful consideration to these risks and uncertainties.